We report on the pharmacokinetics (PK) and pharmacodynamics (PD) of high-dose (>15 mg/kg of body weight per day) amikacin. A mean (standard deviation [SD]) maximum drug concentration in the serum (C max ) and 24-h area under the concentration-time curve (AUC 24 ) of 101 (49.4) mg/liter and 600 (387) mg · h/liter, respectively, were observed (n ‫؍‬ 73) with 28.0 (8.47) mg/kg/day doses. An initial amikacin dose of 2,500 mg in adults weighing 40 kg to 200 kg with therapeutic drug monitoring to adjust the maintenance dose will optimize its PK and PD.
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A mikacin is an important component of an initial empirical antimicrobial treatment strategy against major Gram-negative pathogens associated with serious infections. The regulatory approved dose of this aminoglycoside is 15 mg/kg of body weight per day as 2 to 3 divided doses (1) . Aminoglycoside dosing has shifted from divided daily dosing to single daily dosing in order to optimize its concentration-dependent pharmacokinetic-pharmacodynamic (PK-PD) profile (2, 3) . This dosing paradigm seeks to achieve a maximum concentration of drug in the serum (C max )/ MIC of 8 to 10 and an area under the concentration-time curve (AUC)/MIC of 75 (3) (4) (5) . As a consequence, currently accepted standard doses of aminoglycosides, such as tobramycin, are now administered 5 to 10 mg/kg once daily in patients with normal kidney function, that is roughly 2-fold higher than the regulatory approved dose of 3 to 5 mg/kg/day in divided doses (5) .
The typical 4-fold higher MIC 90 (4 to 8 mg/liter) of amikacin against Pseudomonas aeruginosa compared to tobramycin (1 to 2 mg/liter) coupled with the dose proportionality of aminoglycosides led our institution to adopt an initial empirical amikacin dose of 24 mg/kg in noncritically ill patients and 30 to 40 mg/kg in critically ill patients. Two amikacin concentrations are measured, at 1 to 2 h and at 8 to 10 h after the end of infusion of this first dose, to permit dose individualization (6) . Recent clinical studies corroborate this approach by suggesting that an initial amikacin dose Ն25 mg/kg is likely needed as empirical therapy of certain Gramnegative infections (7) (8) (9) (10) . Herein, we report on the amikacin exposure profile observed in our patients with this higher-thanregulatory-approved amikacin treatment strategy (1) . We also provide a clear rationale for the consideration of an alternate empirical fixed amikacin dosing strategy in line with the current clinical adult total body weight (TBW) distribution.
After institution review board approval, patients Ն21 years of age who received at least one dose of amikacin from 1 January 2012 to 30 June 2014, who had two serial amikacin measurable concentrations, and who had an estimated creatinine clearance (CL CR ) Ͼ30 ml/min based on the Cockcroft-Gault equation were included (11) . Information pertaining to patient demographics, laboratory values, amikacin dose, administration and infusion times, amikacin concentration, and sample collection times were collected. Amikacin concentrations were measured by an automated turbidometry immunoassay using the UniCel DxC 880i Synchron Access clinical system (Beckman Coulter, Brea, CA). Serum creatinine concentrations were quantified based on an isotopic dilution mass spectrometry referenced method that was not modified during the study period. The concentration-time data were fit by population PK analyses (Adapt 5; BMSR, Los Angeles, CA) using a 1-compartment model and a 2-compartment model (12) . The relationship of amikacin PK parameters and exposure to body size were evaluated by visual inspection of scatter plots followed by regression. The final model was selected based on the Akaike information criterion (AIC) (13) . The final model was used to generate empirical Bayesian estimates of individual AUC 24 , C max , and minimum drug concentration in the serum (C min ) values. The C max was the estimated concentration at the end of infusion, and the C min was the estimated concentration 24 h from the start of infusion. Classification and regression tree analysis (CART) was used to identify amikacin doses associated with achievement of a C max /MIC of Ն10 and an AUC 24 /MIC of Ն75 based on an MIC 90 of 8 mg/liter. These results were used to define doses (1-h infusion) for Monte Carlo simulation (MCS) and permit calculation of the cumulative fraction of response (CFR) for a C max /MIC of Ն10 and an AUC 24 /MIC of Ն75 targets and the EUCAST MIC distribution of amikacin against P. aeruginosa (14, 15) . Some institutions define amikacin doses based on a calculated dosing weight (DW) algorithm of (i) TBW if less than ideal body weight (IBW); (ii) IBW if TBW is Ͻ1.2-fold higher than IBW; or (iii) adjusted body weight (ABW) if TBW is Ն1.2-fold higher than IBW (2) . As a result, we also tested the CFR associated with amikacin doses that may be calculated by DW. Descriptive statistics, CART analyses, CFR computation, and figures were generated using Stata/SE, version 13.1.
A total of 218 adult cases received amikacin, and 145 cases were excluded due to an absence of two measurable amikacin concentrations (n ϭ 120), doses Ͻ15 mg/kg of TBW/day (n ϭ 8), amikacin administration time not charted (n ϭ 5), and creatinine clearance Ͻ30 ml/min (n ϭ 10). Two cases were excluded as outliers due to a very low serum creatinine value and incorrect body size data to appropriately estimate CL CR . Table 1 based on receipt of a mean (SD) dose of 2,262 (869) mg or 28.0 (8.47) mg/kg (TBW) or 31.8 (9.60) mg/kg (DW). A majority of patients in the study were white (92.9%) and male (65.9%), and 45.3% were critically ill. About 37.0% of patients were obese based on a body mass index (BMI) of Ն30 kg/m 2 . Most of the patients had TBW of Ͻ80 kg (46.6%) or 80 to Ͻ120 kg (45.2%) and had DW of Ͻ60 kg (32.8%) or 60 to Ͻ90 kg (56.2%). The relationship of amikacin V c and V p with TBW or DW was weak (R 2 Ͻ 0.1) and not significant (P Ͼ 0.1). Similarly, the amikacin CL was correlated to age and serum creatinine but not to TBW or DW. Consistent with this observation, the amikacin C max and AUC 24 were better correlated to amikacin dose in milligrams (R 2 Ͻ 0.32 and 0.39, respectively) than to the dose in milligrams per kilograms (TBW or DW) (R 2 Ͻ 0.13). The relative hazard ratio (RHR) by CART analyses to achieve or not achieve a C max /MIC of Ն10 was 0.50 and 1.46 for doses above and below 2,200 mg, respectively. Similarly, the RHR to achieve or not achieve AUC 24 /MIC of Ն75 was 0.38 and 1.89 for doses above and below 2,500 mg, respectively. Only 63.0% and 36.9% of our patients achieved these C max /MIC and AUC 24 /MIC targets, respectively.
The mean (SD) MCS predicted C max and AUC 24 values and CFR are provided in Table 2 and centered on TBW-based and DW-based doses and a fixed dosing approach. The CFR exceeded 90% for a C max /MIC of Ն10 when the amikacin dose was 30 mg/kg of TBW, 40 mg/kg of DW, or 2,500 mg. However, the CFR was consistently higher with a fixed-dose approach compared to weight-based dosing for an AUC 24 /MIC Ն75. Figure 1 illustrates (16) . Their analysis elegantly demonstrates the relationship of amikacin volume of distribution and weight to be weak and to not serve as a good scalar for dosing (10) . We clearly show that the regulatory approved dose of 15 mg/kg/day is expected to be suboptimal based on PK-PD targets. Recent studies have suggested that doses of Ն25 mg/kg are necessary to optimize the PK-PD profile (7) (8) (9) (10) . However, these studies have not simulated the effect of a fixed dose in their population models, even though weight is not shown to be a proportionate scalar of key PK parameters (7, 8) . We illustrate the predicted effects of both approaches that match our observations (Fig. 1) . If rapid target attainment and short-term use of amikacin are the empirical goals to optimize effect and safety, respectively, then the use of a single initial 2,500 mg dose of amikacin followed by TDM to individualize the dose is suggested (17) . This suggestion, if validated by other groups, not only is simpler across the clinical weight distribution but also should increase the likelihood of effect against serious Gram-negative pathogens.
Our study has several limitations that would be expected of a retrospective design. We included a heterogeneous clinical population who received weight-based doses of amikacin and not a fixed dose, as is proposed by these results. Our model is based on a small and heterogeneous study population but closely matches the PK system parameters reported by recent studies (7, 8) . Based on our results, an initial dose of at least 2,500 mg of amikacin increases the expected CFR, and this mathematical expectation can be validated by other research groups. The increasing use of this agent against serious multidrug-resistant Gram-negative infections and the availability of a commercial assay make this suggested shift in the dosing paradigm testable by other research groups prior to broad implementation.
